Terry Spark Corwin, MD | |
4310 Colby Ave, Suite 203, Everett, WA 98203-2338 | |
(425) 252-8102 | |
(425) 339-0835 |
Full Name | Terry Spark Corwin |
---|---|
Gender | Male |
Speciality | Urology |
Experience | 28 Years |
Location | 4310 Colby Ave, Everett, Washington |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1912954744 | NPI | - | NPPES |
340020074 | Other | WA | RAILROAD MEDICARE |
MD00040591 | Other | WA | STATE LICENSE NUMBER |
0160332 | Other | WA | LABOR AND INDUSTRY |
8311342 | Medicaid | WA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208800000X | Urology | MD00040591 (Washington) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Parkland Health & Hospital System | Dallas, TX | Hospital |
Ut Southwestern University Hospital - William P. Clements Jr. | Dallas, TX | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
University Of Texas Southwestern Medical Center | 0648188250 | 2588 |
News Archive
According to a new study eating out does not necessarily have to mean consuming large portions of high-calorie foods and becoming obese.
An interdisciplinary team of researchers at UC Santa Barbara has produced a groundbreaking study of how nanoparticles are able to biomagnify in a simple microbial food chain.
Results of an advanced clinical trial of an antiretroviral-based microbicide candidate are being announced at the International AIDS Conference in Vienna, Austria. The CAPRISA 004 trial, which tested the safety and effectiveness of 1% tenofovir gel among nearly 900 women at two sites in South Africa, found that using the gel before and after sex provided moderate protection against sexually transmitted HIV.
Epitherix, LLC, a privately held company focused on the discovery and development of novel Wnt pathway small molecule inhibitors for epithelial and leukemic cancers, today announced that it has identified multiple chemical scaffolds that are potent and selective against colorectal carcinoma. "We're very encouraged by our in vitro and in vivo data, especially considering the difficulty in drugging this pathway to date," said Dr. Osman Kibar, CEO of Epitherix.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced it has received a $5 million milestone payment from Biogen Idec International GmbH, a subsidiary of Biogen Idec, Inc., for the selection of the first humanized antibody development candidate from its ErbB3 program.
› Verified 1 days ago
Entity Name | University Of Texas Southwestern Medical Center At Dallas |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1972579365 PECOS PAC ID: 0648188250 Enrollment ID: O20031106000792 |
News Archive
According to a new study eating out does not necessarily have to mean consuming large portions of high-calorie foods and becoming obese.
An interdisciplinary team of researchers at UC Santa Barbara has produced a groundbreaking study of how nanoparticles are able to biomagnify in a simple microbial food chain.
Results of an advanced clinical trial of an antiretroviral-based microbicide candidate are being announced at the International AIDS Conference in Vienna, Austria. The CAPRISA 004 trial, which tested the safety and effectiveness of 1% tenofovir gel among nearly 900 women at two sites in South Africa, found that using the gel before and after sex provided moderate protection against sexually transmitted HIV.
Epitherix, LLC, a privately held company focused on the discovery and development of novel Wnt pathway small molecule inhibitors for epithelial and leukemic cancers, today announced that it has identified multiple chemical scaffolds that are potent and selective against colorectal carcinoma. "We're very encouraged by our in vitro and in vivo data, especially considering the difficulty in drugging this pathway to date," said Dr. Osman Kibar, CEO of Epitherix.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced it has received a $5 million milestone payment from Biogen Idec International GmbH, a subsidiary of Biogen Idec, Inc., for the selection of the first humanized antibody development candidate from its ErbB3 program.
› Verified 1 days ago
Mailing Address | Practice Location Address |
---|---|
Terry Spark Corwin, MD Po Box 3360, Portland, OR 97208-3360 Ph: (866) 747-2455 | Terry Spark Corwin, MD 4310 Colby Ave, Suite 203, Everett, WA 98203-2338 Ph: (425) 252-8102 |
News Archive
According to a new study eating out does not necessarily have to mean consuming large portions of high-calorie foods and becoming obese.
An interdisciplinary team of researchers at UC Santa Barbara has produced a groundbreaking study of how nanoparticles are able to biomagnify in a simple microbial food chain.
Results of an advanced clinical trial of an antiretroviral-based microbicide candidate are being announced at the International AIDS Conference in Vienna, Austria. The CAPRISA 004 trial, which tested the safety and effectiveness of 1% tenofovir gel among nearly 900 women at two sites in South Africa, found that using the gel before and after sex provided moderate protection against sexually transmitted HIV.
Epitherix, LLC, a privately held company focused on the discovery and development of novel Wnt pathway small molecule inhibitors for epithelial and leukemic cancers, today announced that it has identified multiple chemical scaffolds that are potent and selective against colorectal carcinoma. "We're very encouraged by our in vitro and in vivo data, especially considering the difficulty in drugging this pathway to date," said Dr. Osman Kibar, CEO of Epitherix.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced it has received a $5 million milestone payment from Biogen Idec International GmbH, a subsidiary of Biogen Idec, Inc., for the selection of the first humanized antibody development candidate from its ErbB3 program.
› Verified 1 days ago
Brian Chi-ming Fong, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 4310 Colby Ave, Suite 203, Everett, WA 98203 Phone: 425-252-8102 Fax: 425-339-0835 | |
Gary Stack, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 4310 Colby Ave, Suite 203, Everett, WA 98203 Phone: 425-252-8102 | |
Dr. Christopher Robert Hempel, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 3901 Hoyt Ave, Everett, WA 98201 Phone: 425-339-5443 Fax: 425-317-3935 | |
Dr. Yen-huang Chen, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 3901 Hoyt Ave, Everett, WA 98201 Phone: 425-339-5443 Fax: 425-317-3935 | |
Dr. Jeong Hoon Yoon, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 3901 Hoyt Ave, Everett, WA 98201 Phone: 425-339-5443 Fax: 425-317-3935 | |
Raymond K Whalen, MD Urology Medicare: Medicare Enrolled Practice Location: 3901 Hoyt Ave, Everett, WA 98201 Phone: 425-258-3903 | |
Earl Dan Bardin, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 4225 Hoyt, Ste C, Everett, WA 98203 Phone: 425-252-2313 Fax: 425-258-1182 |